Tyra Biosciences, Inc. (TYRA) Stock

HealthcareBiotechnology Website

4 of the hedge funds AlphaScala tracks reported TYRA in 13F filings for the quarter ended Jun 30, 2026; the largest reported position is Marshall Wace's at $18.63M. Company insiders reported 1 open-market buy and 0 sales on SEC Form 4 in the 90 days to Oct 21, 2026.

Which hedge funds own TYRA?

From 13F filings
FundShares HeldPosition ValueChange vs prior Q
Marshall Wace583K$18.63M+195%
Citadel
Ken Griffin
278K$8.89M+1708%
Millennium Management
Israel Englander
178K$5.67M-20%
D.E. Shaw
David Shaw
20K$644.8KNEW

13F holdings as of Jun 30, 2026

Explore all tracked funds →

Are Tyra Biosciences, Inc. insiders buying or selling?

SEC Form 4 filings
90 days to Oct 21, 2026
Buys
1
Sells
0
Net $
+$20K
Unique insiders
1
DateInsiderRoleTypeSharesValue
Sep 9, 26Verjee RehanDirectorBUY971.894$20K

SEC Form 4 filings as of Oct 21, 2026

See cluster-buy signals across all tickers →

TYRA price chart

Powered by TradingView

What does Tyra Biosciences, Inc. do?

Tyra Biosciences Inc. is a biotechnology company focused on developing precision therapies to address drug resistance in cancer treatments. Founded with the mission to advance cancer therapy through targeted innovation, Tyra Biosciences specializes in creating small-molecule inhibitors that can overcome the limitations of current treatments. The company's research and development efforts concentrate on specific gene alterations that drive drug resistance, thereby crafting solutions with the potential to improve patient outcomes. Tyra Biosciences plays a pivotal role in the healthcare sector, particularly in the field of oncology, where the demand for more effective and personalized treatment options is growing. The company leverages cutting-edge technology and deep molecular understanding, aiming to then translate these scientific insights into viable clinical products. While its innovations are currently most impactful within oncology, the methodologies and discoveries could extend to other diseases characterized by resistance mechanisms. Being a part of the competitive biotechnology market, Tyra Biosciences contributes to the ongoing development of novel therapeutics that aim to meet unmet medical needs, thus enhancing its significance in the efforts toward more robust cancer treatment solutions.

CEO
Dr. Todd Harris Ph.D.
Employees
87
Ask about TYRAAI research agent